Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education & Research, Chennai, India.
Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Cancer Research UK City of London Centre, London, UK.
Investig Clin Urol. 2024 Nov;65(6):527-539. doi: 10.4111/icu.20240229.
Biomarkers are molecules such as proteins, genes, or other substances that may be tested to determine the stage of the tumor in a patient. The role of prostate cancer biomarkers is pivotal and the combination of prostate cancer immunotherapy with efficient biomarkers has emerged as a beneficial treatment strategy and its use has increased rapidly. The two primary objectives of this current prostate cancer early detection programs were recognizing non-symptomatic individuals with prostate cancer requiring prostatic core biopsy and identifying men with prostate cancer who might benefit from definitive medical treatment. The progress that has been made so far in the identification of the biomarkers that can be used for the classification, prediction and prognostication of prostate cancer, and as major targets for its clinical intervention has been well summarized in this review.
生物标志物是指可以检测的分子,如蛋白质、基因或其他物质,以确定患者肿瘤的阶段。前列腺癌生物标志物的作用至关重要,将前列腺癌免疫疗法与有效的生物标志物结合已成为一种有益的治疗策略,其应用已迅速增加。目前前列腺癌早期检测计划的两个主要目标是识别需要前列腺核心活检的无症状前列腺癌患者和识别可能受益于确定性治疗的前列腺癌患者。本综述很好地总结了目前在鉴定可用于前列腺癌分类、预测和预后以及作为其临床干预主要靶点的生物标志物方面取得的进展。